Longevity PapersAbout
← All papers
RESEARCH PAPER / 2026-08-07

Attenuating LRRK2 activity ameliorates progerin-induced aging phenotypes in HGPS models and during physiological aging

Mann, L., Herrera-Rodriguez, R., van der Walt, F., Brimacombe, K. R., Sadouki, S., Misteli, T., Kubben, N., Padeken, J.

Institute of Molecular Biology gGmbH (IMB) · biorxiv

Abstract

Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare premature aging disorder caused by progerin, a truncated lamin A variant generated by a silent de novo mutation activating a cryptic splice site in LMNA. The resulting morphological, epigenetic, genomic, and proteostasic defects closely recapitulate some hallmarks of cellular aging. Here, we identify the Parkinson's disease-associated kinase LRRK2 as a critical regulator of HGPS pathology and physiological aging. Rab29-mediated LRRK2 hyperactivation exacerbates progerin-induced cellular aging, whereas LRRK2 knockdown or overexpression of its opposing phosphatase, PPM1H, ameliorates progerin-induced defects. Progerin-expressing cells exhibit altered intracellular trafficking, which is regulated by LRRK2 and links diverse aging hallmarks. Consistent with these findings, reducing LRRK2 levels mitigates cellular aging phenotypes in physiologically aged cells, and loss of the C. elegans ortholog lrk-1 preserves aging-associated loss of motility and extends organismal lifespan. Together, our findings establish LRRK2 as a central node in cellular aging and position it as a potential therapeutic target for aging-related defects in both HGPS and physiological aging.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper identifies LRRK2 as a regulator of progerin-induced aging and physiological aging, demonstrating that attenuating its activity ameliorates aging phenotypes in cellular and organismal models. This work is relevant because it targets fundamental aging mechanisms (proteostasis, intracellular trafficking) rather than just treating symptoms, although the findings represent an incremental advance in understanding specific molecular nodes in aging rather than a transformative breakthrough.

Author of this paper? Send a correction.